Lifelong Surveillance and Managing Cancer Risk in CHH
Last updated:
Cartilage-Hair Hypoplasia (CHH) requires lifelong surveillance due to an increased risk of lymphoma and skin cancer. A multidisciplinary team should regularly monitor the patient's skin, lungs, oral health, and immune function to catch potential complications early and ensure a healthy life.
Key Takeaways
- • Patients with CHH face an increased lifelong risk of non-Hodgkin lymphoma and basal cell carcinoma.
- • A multidisciplinary medical team should manage a structured surveillance schedule that includes skin, lung, dental, and blood screenings.
- • The Epstein-Barr virus (EBV) can be a driver for certain cancers in CHH due to the body's weakened immune response.
- • Women with CHH generally have normal fertility but will almost always require a planned C-section due to cephalo-pelvic disproportion.
- • Regular gynecologic screenings like Pap smears are vital because immune issues can make it harder to clear the Human Papillomavirus (HPV).
Cartilage-Hair Hypoplasia (CHH) is a lifelong condition that requires consistent, proactive monitoring [1]. While the diagnosis brings unique challenges, a structured surveillance plan allows you to stay ahead of potential issues [1]. The goal of surveillance is not just to find problems, but to ensure your child lives a full, active life with the support they need [2].
Managing Cancer Risk
Children and adults with CHH have an increased risk of certain cancers, particularly non-Hodgkin lymphoma and basal cell carcinoma (a common skin cancer) [3]. This risk exists because the genetic defect in the RMRP gene can affect how cells control their growth and how the immune system “polices” abnormal cells [4].
- Lymphoma Risk: The most common type is Diffuse Large B-cell Lymphoma (DLBCL) [3]. This risk is lifelong and can occur even if a person’s immune deficiency seems mild [5].
- Skin Cancer Risk: CHH is associated with an increased risk of basal cell carcinomas, making sun protection and regular skin checks essential [5].
- The EBV Connection: The Epstein-Barr virus (EBV), which causes “mono,” is a known driver of certain cancers in CHH patients because their immune systems may struggle to keep the virus in check [6].
Lifelong Surveillance Schedule
Surveillance should be managed by a multidisciplinary team that includes immunologists, hematologists, and primary care doctors [1].
| Area of Focus | Recommended Action | Why it Matters |
|---|---|---|
| Skin | Annual total-body skin exams by a dermatologist [5]. | To catch basal cell carcinomas early when they are easiest to treat [5]. |
| Lungs | Periodic lung imaging (such as HRCT) as recommended by your team [7]. | To monitor for bronchiectasis, a condition where lung airways become damaged [7]. |
| Oral Health | Frequent dental check-ups focused on the gums [8]. | CHH patients have a higher risk of deep gum pockets and mouth sores [8]. |
| Blood Work | Regular labs to check blood counts and immune markers [9]. | To monitor for anemia and signs of immune system changes [9]. |
Looking Ahead to Adulthood
While reading about future risks can be emotionally jarring for the parent of a newly diagnosed child, it is reassuring to know that these are long-term considerations with established protocols. Your child’s medical team will help you transition these responsibilities to them as they grow.
For girls with CHH, the long-term outlook for reproductive health is generally positive, though it requires specialized care [2].
- Puberty: Most girls with CHH begin puberty at a normal age, though they may not experience a typical “growth spurt” due to their skeletal dysplasia [2]. In some cases, hormone replacement therapy may be needed if puberty is delayed [10].
- Fertility: Research suggests that many women with CHH have normal ovarian function and can conceive [11].
- Pregnancy and Delivery: Pregnancy in women with CHH requires a multidisciplinary team [12]. Due to the small size of the pelvis (cephalo-pelvic disproportion), almost all women with CHH will require a planned Cesarean section (C-section) [12].
- Gynecologic Care: Because immune issues can make it harder to clear the Human Papillomavirus (HPV), regular screenings (like Pap smears) are vital to prevent cervical cancer [11].
By staying consistent with these screenings, you can help your child navigate the risks of CHH and focus on their growth, education, and future.
Frequently Asked Questions
Why do people with CHH have a higher risk of cancer?
What types of cancer are most common in Cartilage-Hair Hypoplasia?
How does the Epstein-Barr virus (EBV) affect CHH patients?
Can women with CHH have a safe pregnancy and delivery?
What routine medical screenings are needed for someone with CHH?
Questions for Your Doctor
- • What is our specific schedule for skin cancer checks and blood work to monitor for lymphoma?
- • Should we start monitoring for the Epstein-Barr virus (EBV), and if so, how often?
- • When should my child have their first lung scan to check for bronchiectasis?
- • How often should our child see a dentist for specialized periodontal (gum) exams?
- • Are there specific gynecologic screenings my daughter will need earlier or more often than her peers?
Questions for You
- • How can I help my child become comfortable with regular medical check-ups from a young age?
- • What is our plan for transitioning my child's medical records and surveillance schedule to them when they become an adult?
- • Have I noticed any new or changing moles, or any persistent lumps or bumps on my child's skin?
- • What are our primary goals for my child's long-term quality of life and independence?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management.
Vakkilainen S, Taskinen M, Mäkitie O
Scandinavian journal of immunology 2020; (92(4)):e12913 doi:10.1111/sji.12913.
PMID: 32506568 - 2
Gynecologic health in cartilage-hair hypoplasia: A survey of 26 adult females.
Holopainen E, Vakkilainen S, Mäkitie O
American journal of medical genetics. Part A 2019; (179(2)):190-195 doi:10.1002/ajmg.a.60684.
PMID: 30561899 - 3
Lymphomas in cartilage-hair hypoplasia - A case series of 16 patients reveals advanced stage DLBCL as the most common form.
Kukkola HL, Utriainen P, Huttunen P, et al.
Frontiers in immunology 2022; (13()):1004694 doi:10.3389/fimmu.2022.1004694.
PMID: 36211439 - 4
The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2.
Vakkilainen S, Skoog T, Einarsdottir E, et al.
Scientific reports 2019; (9(1)):13758 doi:10.1038/s41598-019-50334-6.
PMID: 31551465 - 5
A 30-Year Prospective Follow-Up Study Reveals Risk Factors for Early Death in Cartilage-Hair Hypoplasia.
Vakkilainen S, Taskinen M, Klemetti P, et al.
Frontiers in immunology 2019; (10()):1581 doi:10.3389/fimmu.2019.01581.
PMID: 31379817 - 6
Refractory/Relapsed Hodgkin Lymphoma in Cartilage Hair Hypoplasia-Anauxetic Dysplasia Spectrum: Long-term HSCT-free Remission in 2 Pediatric Siblings.
Bukhari SI, Yazdani S, Fadoo Z
Journal of pediatric hematology/oncology 2026; (48(2)):e91-e96 doi:10.1097/MPH.0000000000003158.
PMID: 41460196 - 7
Pulmonary Follow-Up Imaging in Cartilage-Hair Hypoplasia: a Prospective Cohort Study.
Vakkilainen S, Klemetti P, Martelius T, et al.
Journal of clinical immunology 2021; (41(5)):1064-1071 doi:10.1007/s10875-021-01007-5.
PMID: 33675005 - 8
Oral findings in patients with cartilage-hair hypoplasia - cross-sectional observational study.
Arponen H, Vakkilainen S, Rautava J, Mäkitie O
Orphanet journal of rare diseases 2023; (18(1)):147 doi:10.1186/s13023-023-02758-7.
PMID: 37308912 - 9
Anemia in patients with cartilage hair hypoplasia: a narrative review and recommendations.
Lewandowska N, Ordak M
Laboratory medicine 2025; (56(3)):213-219 doi:10.1093/labmed/lmae082.
PMID: 39321258 - 10
Diversity of Pubertal Development in Cartilage-Hair Hypoplasia; Two Illustrative Cases.
Holopainen E, Vakkilainen S, Mäkitie O
Journal of pediatric and adolescent gynecology 2018; (31(4)):422-425 doi:10.1016/j.jpag.2018.02.128.
PMID: 29462708 - 11
Gynecologic assessment of 19 adult females with cartilage-hair hypoplasia - high rate of HPV positivity.
Holopainen E, Vakkilainen S, Mäkitie O
Orphanet journal of rare diseases 2018; (13(1)):207 doi:10.1186/s13023-018-0945-9.
PMID: 30445974 - 12
Outcomes of 42 pregnancies in 14 women with cartilage-hair hypoplasia: a retrospective cohort study.
Holopainen E, Vakkilainen S, Mäkitie O
Orphanet journal of rare diseases 2020; (15(1)):326 doi:10.1186/s13023-020-01614-2.
PMID: 33213509
This page provides educational information on CHH surveillance and cancer risks. It does not replace professional medical advice. Always consult your multidisciplinary healthcare team for a personalized screening schedule.
Stay up to date
Get notified when new research about Cartilage-hair hypoplasia is published.
No spam. Unsubscribe anytime.